Contemporary management of uncomplicated urinary tract infections

Drugs

Volumn 68, Issue 9, 2008, Pages 1169-1205

  Guay, David R P ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Urinary tract infections, diagnosis; Urinary tract infections, treatment

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; BETA LACTAM ANTIBIOTIC; CEFACLOR; CEFADROXIL; CEFALEXIN; CEFRADINE; CEFUROXIME AXETIL; CEPHALOSPORIN DERIVATIVE; CIPRO XL; CIPROFLOXACIN; COTRIMOXAZOLE; FOSFOMYCIN; LEVOFLOXACIN; NITROFURANTOIN; NORFLOXACIN; OFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TRIMETHOPRIM;

ANTIBIOTIC RESISTANCE; COST CONTROL; DIAGNOSTIC TEST; DISEASE COURSE; DRUG COST; GASTROINTESTINAL SYMPTOM; HEALTH CARE COST; HUMAN; INFECTION PREVENTION; INFECTION RISK; LABORATORY TEST; PATHOPHYSIOLOGY; PATIENT COMPLIANCE; PRACTICE GUIDELINE; REVIEW; THRUSH; URINARY TRACT INFECTION; VAGINA CANDIDIASIS;

ADULT; ANTI-INFECTIVE AGENTS, URINARY; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUG THERAPY, COMBINATION; FEMALE; FLUOROQUINOLONES; HUMANS; MALE; NITROFURANTOIN; PRACTICE GUIDELINES AS TOPIC; RECURRENCE; TRIMETHOPRIM-SULFAMETHOXAZOLE COMBINATION; URINARY TRACT INFECTIONS;

ESCHERICHIA COLI; KLEBSIELLA; PROTEUS MIRABILIS; STAPHYLOCOCCUS SAPROPHYTICUS;

EID: 44949180108     PISSN: 00126667     EISSN: 00126667     Source Type: Journal    
DOI: 10.2165/00003495-200868090-00002     Document Type: Review

References (141)

1. Richards DA, Toop LJ, Chambers ST, et al. Antibiotic resistance in uncomplicated urinary tract infection: problems with interpreting cumulative resistance rates from local community laboratories. New Zealand Med J 2002 Jan 25; 115 (1146): 12-4
2. Car J. Urinary tract infections in women: diagnosis and management in primary care. BMJ 2006 Jan 14; 332 (7533): 94-7
3. Czaja CA, Hooton TM. Update on acute uncomplicated urinary tract infection in women. Postgrad Med 2006 Jun-Jul; 119(1): 39-45
4. Foxman B, Brown P. Epidemiology of urinary tract infections: transmission and risk factors, incidence, and costs. Infect Dis Clin North Am 2003 Jun; 17 (2): 227-41
5. Bass 3rd PF, Jarvis JA, Mitchell CK. Urinary tract infections. Prim Care Clin 2003 Mar; 30 (1): 41-61
6. Ki M, Park T, Choi BY, et al. The epidemiology of acute pyelonephritis in South Korea, 1997-1999. Am J Epidemiol 2004; 160: 985-93
7. Laupland KB, Ross T, Pitout JD, et al. Community-acquired urinary tract infections: a population-based assessment. Infection 2007 Jun; 35 (3): 150-3
8. Hooton TM. The current management strategies for community-acquired urinary tract infection. Infect Dis Clin North Am 2003 Jun; 17 (2): 303-32
9. Naber KG, Bergman B, Bishop MC, et al. EAU guidelines for the management of urinary and male genital tract infections. Eur Urol 2001; 40: 576-88
10. Ferry SA, Holm SE, Stenlund H, et al. The natural course of uncomplicated lower urinary tract infection in women illustrated by a randomized placebo controlled study. Scand J Infect Dis 2004; 36 (4): 296-301
11. Godaly G, Svanborg C. Urinary tract infections revisited. Kidney Int 2007 Apr; 71 (8): 721-3
12. Bullitt E, Makowski L. Structure polymorphism of bacterial adhesion pili. Nature 1995; 373: 164-7
13. Bergsten G, Wullt B, Schembri MA, et al. Do type 1 fimbriae promote inflammation in the human urinary tract? Cell Microbiol 2007 Jul; 9 (7): 1766-81
14. Ulett GC, Valle J, Beloin C, et al. Functional analysis of antigen 43 in uropathogenic Escherichia coli reveals a role in long-term persistence in the urinary tract. Infect Immunol 2007 Jul; 75 (7): 3233-44
15. Zasloff M. Antimicrobial peptides, innate immunity, and the normally sterile urinary tract. J Am Soc Nephrol 2007; 18: 2810-6
16. O'Brien K, Hillier S, Simpson S, et al. An observational study of empirical antibiotics for adult women with uncomplicated UTI in general practice. J Antimicrob Chemother 2007 Jun; 59 (6): 1200-3
17. Nys S, van Merode T, Bartelds AI, et al. Urinary tract infections in general practice patients: diagnostic tests versus bacteriological culture. J Antimicrob Chemother 2006 May; 57 (5): 955-8
18. McIsaac WJ, Low DE, Biringer A, et al. The impact of empirical management of acute cystitis on unnecessary antibiotic use. Arch Int Med 2002 Mar 10; 162 (5): 600-5
19. Bent S, Nallamothu BK, Simel DL, et al. Does this woman have an acute uncomplicated urinary tract infection? JAMA 2002 May; 287(20): 2701-10
20. Batchelor BI, Crook DW, Jones T, et al. Impact of guidelines for the diagnosis of urinary tract infection on trimethoprim susceptibility of Escherichia coli. J Antimicrob Chemother 2002 Jan; 49 (1): 223-4
21. Gupta K, Scholes D, Stamm WE. Increasing prevalence of antimicrobial resistance among uropathogens causing acute uncomplicated cystitis in women. JAMA 1999 Feb 24; 281 (8): 736-8
22. Karlowsky JA, Kelly LJ, Thornsberry C, et al. Susceptibility to fluoroquinolones among commonly isolated gram-negative bacilli in 2000; TRUST and TSN data for the United States. Int J Antimicrob Agents 2002; 19: 21-31
23. Gupta K, Sahm DF, Mayfield D, et al. Antimicrobial resistance among uropathogens that cause community-acquired urinary tract infections in women: a nationwide analysis. Clin Infect Dis 2001 Jul 1; 33 (1): 89-94
24. Karlowsky JA, Hoban DJ, Decorby MR, et al. Fluoroquinolone-resistant urinary isolates of Escherichia coli from outpatients are frequently multidrug resistant: results from the North American Urinary Tract Infection Collaborative Alliance-Quinolone Resistance study. Antimicrob Agents Chemother 2006 Jun; 50 (6): 2251-4
25. Kiffer CR, Mendes C, Oplustil CP, et al. Antibiotic resistance and trend of urinary pathogens in general outpatients from a major urban city. Int Braz J Urol 2007 Jan-Feb; 33(1): 42-49
26. Goldstein FW. Antibiotic susceptibility of bacterial strains isolated from patients with community-acquired urinary tract infections in France. Eur J Clin Microbiol Infect Dis 2000; 19: 112-7
27. Hummers-Pradier EVA, Koch M, Ohse AM, et al. Antibiotic resistance of urinary pathogens in female general practice patients. Scand J Infect Dis 2005; 37 (4): 256-61
28. Ungheri D, Albini E, Belluco G. In-vitro susceptibility of quinolone-resistant clinical isolates of Escherichia coli to fosfomycin trometamol. J Chemother 2002 Jun; 14 (3): 237-40
29. Marchese A, Gualco L, Debbia EA, et al. In vitro activity of fosfomycin against gram-negative urinary pathogens and the biological cost of fosfomycin resistance. Int J Antimicrob Agents 2003 Oct; 22 Suppl. 2: 53-9
30. Tempera G, Mirabile M, Mangiafico A, et al. Fosfomycin trimethamine in uncomplicated urinary tract infections: an epidemiological survey. J Chemother 2004 Apr; 16 (2): 216-7
31. Gesu GP, Marchetti F. Increasing resistance according to patient's age and sex in Escherichia coli isolated from urine in Italy. J Chemother 2007 Apr; 19 (2): 161-5
32. Sociedad Espanola de Enfermedades Infecciosas y Microbiologia Clinica (SEMIC). Protocolos clinicos 2003: infeccion urinaria [online]. Available from URL: http://www.semic.org/protocolos/clinicos/index.htm [Accessed 2007 Nov 12]
33. Hryniewicz K, Szczypa K, Sulikowska A, et al. Antibiotic susceptibility of bacterial strains isolated from urinary tract infections in Poland. J Antimicrob Chemother 2001 Jun; 47 (6): 773-80
34. Zemkova M, Kotlarova J, Merka V, et al. Emergence of fluoroquinolone resistance in Escherichia coli isolates at the department of clinical hematology. New Microbiol 2007 Oct; 30 (4): 423-30
35. Gobernado M, Valdes L, Alos JI, et al. Quinolone resistance in female outpatient urinary tract isolates of Escherichia coli: age-related differences. Rev Esp Quimio 2007; 20: 206-10
36. Gobernado M, Valdes L, Alos JI, et al. Antimicrobial susceptibility of clinical Escherichia coli isolates from uncomplicated cystitis in women over a 1-year period in Spain. Rev Esp Quimio 2007; 20: 68-76
37. Garcia MI, Munoz Bellido JL, Garcia Rodriguez JA, et al. In vitro susceptibility of community-acquired urinary tract pathogens to commonly used antimicrobial agents in Spain: a comparative multicenter study (2002-2004). J Chemother 2007 Jun; 19 (3): 263-70
38. Storby KA, Osterlund A, Kahlmeter G. Antimicrobial resistance in Escherichia coli in urine samples from children and adults: a 12 year analysis. Act Paed 2004 Apr; 93 (4): 487-91
39. Arslan H, Azap OK, Ergonul O, et al. Risk factors for ciprofloxacin resistance among Escherichia coli strains isolated from community-acquired urinary tract infections in Turkey. J Antimicrob Chemother 2005 Nov; 56 (5): 914-8
40. Rock W, Colodner R, Chazan B, et al. Ten years surveillance of antimicrobial susceptibility of community-acquired Escherichia coli and other uropathogens in Northern Israel (1995-2005). Isr Med Assoc J 2007 Nov; 9: 803-5
41. Hima-Lerible H, Menard D, Talarmin A. Antimicrobial resistance among uropathogens that cause community-acquired urinary tract infections in Bangui, Central African Republic. J Antimicrob Chemother 2003 Jan; 51 (1): 192-4
42. Randrianirina F, Soares JL, Carod JF, et al. Antimicrobial resistance among uropathogens that cause community-acquired urinary tract infections in Antananarivo, Madagascar. J Antimicrob Chemother 2007 Feb; 59 (2): 309-12
43. Issack MI, Yee Kin Tet HY, Morlat P. Antimicrobial resistance among enterobacteriaceae causing uncomplicated urinary tract infections in Mauritius: consequences of past misuse of antibiotics. J Chemother 2007 Apr; 19 (2): 222-5
44. Nabeth P, Perrier-Gros-Claude J-D, Juergens-Behr A, et al. In vitro susceptibility of quinolone-resistant Enterobacteriaceae uropathogens to fosfomycin trometamol, in Dakar, Senegal. Scand J Infect Dis 2005; 37 (6-7): 497-9
45. Dromigny JA, Nabeth P, Juergens-Behr A, et al. Risk factors for antibiotic-resistant Escherichia coli isolated from community-acquired urinary tract infections in Dakar, Senegal. J Antimicrob Chemother 2005 Jul; 56 (1): 236-9
46. Ahmed AA, Osman H, Mansour AM, et al. Antimicrobial agent resistance in bacterial isolates from patients with diarrhea and urinary tract infection in the Sudan. Am J Trop Med Hyg 2000; 63: 259-63
47. Akram M, Shahid M, Khan AU. Etiology and antibiotic resistance patterns of community-acquired urinary tract infections in JNMC Hospital Aligarh, India. Ann Clin Microbiol Antimicrob 2007; 6: 4
48. Arya SC, Agarwal N. Re: antibiotic resistance and trend of urinary pathogens in general outpatients from a major urban city. Int Braz J Urol 2007; 33: 267-9
49. Kahlmeter G. An international survey of the antimicrobial susceptibility of pathogens from uncomplicated urinary tract infections: the ECO.SENS Project. J Antimicrob Chemother 2003 Jan; 51 (1): 69-76
50. Urbanek K, Kolar M, Strojil J, et al. Utilization of fluoroquinolones and Escherichia coli resistance in urinary tract infection: inpatients and outpatients. Pharmacoepidemiol Drug Saf 2005 Oct; 14 (10): 741-5
51. Brown PD, Freeman A, Foxman B. Prevalence and predictors of trimethoprim/sulphamethoxazole resistance among uropathogenic Escherichia coli isolates in Michigan. Clin Infect Dis 2002 Apr 15; 34 (8): 1061-6
52. Wright SW, Wrenn KD, Haynes ML. Trimethoprim-sulfamethoxazole resistance among urinary coliform isolates. J Gen Intern Med 1999; 14: 606-9
53. McNulty CAM, Richards J, Livermore DM, et al. Clinical relevance of laboratory-reported antibiotic resistance in acute uncomplicated urinary tract infection in primary care. J Antimicrob Chemother 2006 Nov; 58 (5): 1000-8
54. Hillier S, Roberts Z, Dunstan F, et al. Prior antibiotics and risk of antibiotic-resistant community-acquired urinary tract infection: a case-control study. J Antimicrob Chemother 2007 Jul; 60 (1): 92-9
55. Gupta K, Stamm WE. Outcomes associated with trimethoprim/ sulphamethoxazole (TMP/SMX) therapy in TMP/SMX resistant community-acquired UTI. Int J Antimicrob Agents 2002 Jun; 19 (6): 554-6
56. Metlay JP, Strom BL, Asch DA. Prior antimicrobial drug exposure: a risk factor for trimethoprim-sulfamethoxazole-resistant urinary tract infections. J Antimicrob Chemother 2003 Apr; 51 (4): 963-70
57. Kahan NR, Chinitz DP, Waitman DA, et al. Empiric treatment of uncomplicated urinary tract infection with fluoroquinolones in older women in Israel: another lost treatment option? Ann Pharmacother 2006 Dec; 40 (12): 2223-7
58. Blahna MT, Zalewski CA, Reuer J, et al. The role of horizontal gene transfer in the spread of trimethoprim-sulfamethoxazole resistance among uropathogenic Escherichia coli in Europe and Canada. J Antimicrob Chemother 2006 Apr; 57 (4): 666-72
59. Wright SW, Wrenn KD, Haynes M, et al. Prevalence and risk factors for multidrug resistant uropathogens in ED patients. Am J Emerg Med 2000 Mar; 18 (2): 143-6
60. Mentler PA, Kuhn BR, Gandhi G. Risk stratification for trimethoprim-sulfamethoxazole resistance in community-acquired, uncomplicated urinary tract infections. Am J Health-Syst Pharm 2006 Sep 1; 63 (17): 1588-90
61. Colodner R, Rock W, Chazan B, et al. Risk factors for the development of extended-spectrum beta-lactamase-producing bacteria in nonhospitalized patients. Eur J Clin Microbiol Infect Dis 2004 Mar; 23 (3): 163-7
62. Marijan T, Vranes J, Bedeni B, et al. Emergence of uropathogenic extended-spectrum beta lactamases-producing Escherichia coli strains in the community. Coll Antropol 2007; 31: 227-33
63. Goettsch WG, Janknegt R, Herings RM. Increased treatment failure after 3-day courses of nitrofurantoin and trimethoprim for urinary tract infections in women: a population-based retrospective cohort study using the PHARMO database. Br J Clin Pharmacol 2004 Aug; 58 (2): 184-9
64. Butler CC, Hillier S, Roberts Z, et al. Antibiotic-resistant infections in primary care are symptomatic for longer and increase workload: outcomes for patients with E. coli UTIs. Br J Gen Prac 2006 Sep; 56 (530): 686-92
65. Lawrenson RA, Logie JW. Antibiotic failure in the treatment of urinary tract infections in young women. J Antimicrob Chemother 2001 Dec; 48 (6): 895-901
66. Gupta K. Emerging antibiotic resistance in urinary tract pathogens. Infect Dis Clin North Am 2003 Jun; 17 (2): 243-59
67. Gross PA, Patel B. Reducing antibiotic overuse: a call for a national performance measure for not treating asymptomatic bacteriuria. Clin Infect Dis 2007 Nov 15; 45 (10): 1335-7
68. Hillier S, Bell J, Heginbothom M, et al. When do general practitioners request urine specimens for microbiology analysis? The applicability of antibiotic resistance surveillance based on routinely collected data. J Antimicrob Chemother 2006 Dec; 58 (6): 1303-6
69. Galatti L, Sessa A, Mazzaglia G, et al. Antibiotic prescribing for acute and recurrent cystitis in primary care: a 4 year descriptive study. J Antimicrob Chemother 2006 Mar; 57 (3): 551-6
70. Huang ES, Stafford RS. National patterns in the treatment of urinary tract infections in women by ambulatory care physicians. Arch Int Med 2002 Jan 14; 162 (1): 41-7
71. Kallen AJ, Welch HG, Sirovich BE. Current antibiotic therapy for isolated urinary tract infections in women. Arch Int Med 2006 Mar 27; 166 (6): 635-9
72. Wigton RS, Longenecker JC, Bryan TJ, et al. Variation by specialty in the treatment of urinary tract infection in women. J Gen Int Med 1999 Aug; 14 (8): 491-4
73. Lautenbach E, Larosa LA, Kasbekar N, et al. Fluoroquinolone utilization in the emergency departments of academic medical centers: prevalence of, and risk factors for, inappropriate use. Arch Int Med 2003 Mar 10; 163 (5): 601-5
74. Iravani A, Tice AD, McCarty J, et al. Short-course ciprofloxacin treatment of acute uncomplicated urinary tract infection in women: the minimum effective dose. Arch Intern Med 1995 Mar 13; 155 (5): 485-94
75. Vogel T, Verreault R, Gourdeau M, et al. Optimal duration of antibiotic therapy for uncomplicated urinary tract infection in older women: a double-blind randomized controlled trial. CMAJ 2004 Feb 17; 170 (4): 469-73
76. Arredondo-Garcia JL, Figueroa-Damian R, Rosas A, et al. Comparison of short-term treatment regimen of ciprofloxacin versus long-term treatment regimens of trimethoprim/sulfamethoxazole or norfloxacin for uncomplicated lower urinary tract infections: a randomized, multicentre, open-label, prospective study. J Antimicrob Chemother 2004 Oct; 54 (4): 840-3
77. Hooten TM, Scholes D, Gupta K, et al. Amoxicillin-clavulanate vs ciprofloxacin for the treatment of uncomplicated cystitis in women. a randomized trial. JAMA 2005 Feb 23; 293 (8): 949-55
78. Richard GA, Mathew CP, Kirstein JM, et al. Single-dose fluoroquinolone therapy of acute uncomplicated urinary tract infection in women: results from a randomized, double-blind, multicenter trial comparing single-dose to 3-day fluoroquinolone regimens. Urology 2002 Mar; 59 (3): 334-9
79. Iravani A, Klimberg I, Briefer C, et al. A trial comparing low-dose, short-course ciprofloxacin and standard 7 day therapy with co-trimoxazole or nitroflurantoin in the treatment of uncomplicated urinary tract infections. J Antimicrob Chemother 1999; 43 Suppl. A: 67-75
80. McCarty JM, Richard G, Huck W, et al. A randomized trial of short-course ciprofloxacin, ofloxacin, or trimethoprim/sulfamethoxazole for the treatment of acute urinary tract infection in women. Am J Med 1999 Mar; 106 (3): 292-9
81. Schaeffer AJ, Stuppy BA. Efficacy and safety of self-start therapy in women with recurrent urinary tract infections. J Urol 1999 Jan; 161 (1): 207-11
82. Henry Jr DC, Bettis RB, Riffer E, et al. Comparison of once-daily extended-release ciprofloxacin and conventional twice-daily ciprofloxacin for the treatment of uncomplicated urinary tract infection in women. Clin Ther 2002 Dec; 24 (12): 2088-104
83. Fourcroy JL, Berner B, Chiang YK, et al. Efficacy and safety of a novel once-daily extended-release ciprofloxacin tablet formulation for treatment of uncomplicated urinary tract infection in women. Antimicrob Agents Chemother 2005 Oct; 49 (10): 4137-43
84. Bonfiglio G, Mattina R, Lanzafame A, et al. Fosfomycin tromethamine in uncomplicated urinary tract infections: a clinical study. Chemotherapy 2005 May; 51 (2-3): 162-6
85. Lobel B. Short term therapy for uncomplicated urinary tract infection today: clinical outcome upholds the theories. Int J Antimicrob Agents 2003 Oct; 22 Suppl. 2: 85-7
86. Gupta K, Hooton TM, Stamm WE. Isolation of fluoroquinolone-resistant rectal Escherichia coli after treatment of acute uncomplicated cystitis. J Antimicrob Chemother 2005 Jul; 56 (1): 243-6
87. Stein GE. Comparison of single-dose fosfomycin and a 7-day course of nitrofurantoin in female patients with uncomplicated urinary tract infection. Clin Ther 1999; 21: 1864-72
88. Minassian MA, Lewis DA, Chattopadhyay D, et al. A comparison between single-dose fosfomycin trametamol (Monuril®) and a 5-day course of trimethoprim in the treatment of uncomplicated lower urinary tract infection. Int J Antimicrob Agents 1998; 10: 39-47
89. Raz R, Chazan B, Kennes Y, et al. Empirical use of trimethoprim/ sulphamethoxazole (TMP-SMX) in the treatment of women with uncomplicated urinary tract infections, in a geographical area with a high prevalence of TMP-SMX-resistant uropathogens. Clin Infect Dis 2002 May 1; 34 (9): 1165-9
90. Christiaens TC, DeMeyere M, Verschraegen G, et al. Randomised controlled trial of nitrofurantoin versus placebo in the treatment of uncomplicated urinary tract infection in adult women. Br J Gen Prac 2002 Sep; 52 (482): 729-34
91. Nicolle LE, Madsen KS, Debeeck GO, et al. Three days of pivmecillinam or norfloxacin for treatment of acute uncomplicated urinary infection in women. Scand J Infect Dis 2002; 34 (7): 487-92
92. Hooton TM, Winter C, Tiu F, et al. Randomized comparative trial and cost analysis of 3-day antimicrobial regimens for treatment of acute cystitis in women. JAMA 1995 Jan 4; 273 (1): 41-5
93. Masterton RG, Bochsler JA. High-dose co-amoxiclav in a single dose versus 7 days of co-trimoxazole as treatment of uncomplicated lower urinary tract infection in women. J Antimicrob Chemother 1995 Jan; 35 (1): 129-37
94. Leigh AP, Nemeth MA, Keyserling CH, et al. Cefdinir versus cefaclor in the treatment of uncomplicated urinary tract infection. Clin Ther 2000; 22: 818-25
95. Nicolle LE, Hoepelman AIM, Floor M, et al. Comparison of three days' therapy with cefcanel or amoxicillin for the treatment of acute uncomplicated urinary tract infection. Scand J Infect Dis 1993; 25 (5): 631-7
96. Gupta K, Hooten TM, Roberts PL, et al. Short-course nitrofurantoin for the treatment of acute uncomplicated cystitis in women. Arch Intern Med 2007 Nov 12; 167 (20): 2207-12
97. O'Connor KA, Kingston M, Twomey C, et al. A trial comparing standard trimethoprim therapy with nitrofurantoin in the treatment of uncomplicated urinary tract infections in elderly patients [abstract]. Age Ageing 2002 Feb; 31 Suppl. 1: 13
98. Talan DA, Stamm WE, Hooten TM, et al. Comparison of ciprofloxacin (7 days) and trimethoprim-sulfamethoxazole (14 days) for acute uncomplicated pyelonephritis in women. a randomized trial. JAMA 2000 Mar 22/29; 283(12): 1583-90
99. Rubin RH, Shapiro ED, Andriole VT, et al. Evaluation of new anti-infective drugs for the treatment of urinary tract infection. Clin Infect Dis 1992 Nov; 15 Suppl. 1: S216-27
100. DeAlleaume L, Tweed EM. When are empiric antibiotics appropriate for urinary tract infection symptoms? J Fam Prac 2006 Apr; 55 (4): 338, 341-2
101. Kahan NR, Friedman NL, Lomnicky Y, et al. Physician speciality and adherence to guidelines for the treatment of unsubstantiated uncomplicated urinary tract infection among women. Pharmacoepidemiol Drug Saf 2005 May; 14 (5): 357-61
102. Barry HC, Ebell MH, Hickner J. Evaluation of suspected urinary tract infection in ambulatory women: a cost-utility analysis of office-based strategies. J Fam Prac 1997; 44: 49-60
103. Richards D, Toop L, Chambers S, et al. Response to antibiotics of women with symptoms of urinary tract infection but negative dipstick urine test results: a double-blind randomized controlled trial. BMJ 2005 Jul 16; 331 (7509): 143
104. Ejrnaes K, Sandvang D, Lundgren B, et al. Pulsed-field gel electrophoresis typing of Escherichia coli strains from samples collected before and after pivmecillinam or placebo treatment of uncomplicated community-acquired urinary tract infection in women. J Clin Microbiol 2006 May; 44 (5): 1776-81
105. Rosen DA, Hooten TM, Stamm WE, et al. Detection of intracellular bacterial communities in human urinary tract infections. PLOS Med 2007 Dec; 4 (12): 1949-58
106. Ottiger C, Schaer G, Huber AR. Time-course of quantitative urinary leukocytes and bacteria counts during antibiotic therapy in women with symptoms of urinary tract infection. Clin Chim Acta 2007 Apr; 379 (1-2): 36-41
107. Vinson DR, Quesenberry Jr CP. The safety of telephone management of presumed cystitis in women. Arch Intern Med 2004 May 10; 164 (9): 1026-9
108. Barry HC, Hickner J, Ebell MH, et al. A randomized controlled trial of telephone management of suspected urinary tract infections in women. J Fam Prac 2001 Jul; 50 (7): 589-94
109. Saint S, Scholes D, Fihn SD, et al. The effectiveness of a clinical practice guideline for the management of presumed uncomplicated urinary tract infection in women. Am J Med 1999 Jun; 106 (6): 636-41
110. Aagaard EM, Nadler P, Adler J, et al. An interactive computer kiosk module for the treatment of recurrent uncomplicated cystitis in women. J Gen Int Med 2006 Nov; 21 (11): 1156-9
111. Schauberger CW, Merkitch KW, Prell AM. Acute cystitis in women: experience with a telephone-based algorithm. Wisc Med J 2007; 106 (6): 326-9
112. McIsaac WJ, Moineddin R, Ross S. Validation of a decision aid to assist physicians in reducing unnecessary antibiotic drug use for acute cystitis. Arch Intern Med 2007 Nov 12; 167 (20): 2201-6
113. Gupta K, Hooten TM, Roberts PL, et al. Patient-initiated treatment of uncomplicated recurrent urinary tract infections in young women. Ann Intern Med 2001 Jul 3; 135 (1): 9-16
114. Lee BB, Simpson JM, Craig JC, et al. Methenamine hippurate for preventing urinary tract infections. Cochrane Database Syst Rev 2007; (4): CD003265
115. Albert X, Huertas I, Pereiro II, et al. Antibiotics for preventing recurrent urinary tract infections in non-pregnant women. Cochrane Database Syst Rev 2004; (3): CD001209
116. Alexiou Z, Mouktaroudi M, Koratzanis G, et al. The significance of compliance for the success of antimicrobial prophylaxis in recurrent lower urinary tract infections: the Greek experience. Int J Antimicrob Ag 2007; 30: 40-3
117. Bauer HW, Alloussi S, Egger C, et al. A long-term, multicenter, double-blind study of an Escherichia coli extract (OM-89) in female patients with recurrent urinary tract infections. Eur Urol 2005; 47: 542-8
118. Darouiche RO, Thornby JI, Cerra-Stewart C, et al. Bacterial interference for prevention of urinary tract infection: a prospective, randomized, placebo-controlled, double-blind pilot trial. Clin Infect Dis 2005 Nov 15; 41 (10): 1531-4
119. Barrons R, Tassone D. Use of Lactobacillus probiotics for bacterial genitourinary infections in women: a review. Clin Ther 2008 Mar; 30 (3): 453-68
120. Reid G, Bruce AW. Probiotics to prevent urinary tract infections: the rationale and evidence. World J Urol 2006; 24: 28-32
121. McCully KS, Jackson S. Hormone replacement therapy and the bladder. J Br Menopause Soc 2004 Mar; 10 (1): 30-2
122. Rozenberg S, Pastijn A, Gevers R, et al. Estrogen therapy in older patients with recurrent urinary tract infections: a review. Int J Fertil Womens Med 2004 Mar-Apr; 49(2): 71-74
123. Andre M, Molstad S, Lundborg GS, et al. Management of urinary tract infections in primary care: a repeated 1-week diagnosis-prescribing study in five counties in Sweden in 2000 and 2002. Scand J Infect Dis 2004; 36 (2): 134-8
124. Martinez MA, Inglada L, Ochoa C, et al. Assessment of antibiotic prescription in acute urinary tract infections in adults. J Infect 2007; 54: 235-44
125. Warren JW, Abrutyn E, Hebel JR, et al. Guidelines for antimicrobial treatment of uncomplicated acute bacterial cystitis and acute pyelonephritis. Clin Infect Dis 1999 Oct; 29 (4): 745-58
126. Kahan E, Kahan NR, Chinitz DP. Urinary tract infection in women. Physician's preferences for treatment and adherence to guidelines: a national drug utilization study in a managed care setting. Eur J Clin Pharmacol 2003 Nov; 59 (8-9): 663-8
127. Grover ML, Bracamonte JD, Kanodia AK, et al. Assessing adherence to evidence-based guidelines for the diagnosis and management of uncomplicated urinary tract infection. Mayo Clin Proc 2007 Feb; 82 (2): 181-5
128. O'Connor PJ, Solberg LI, Christianson J, et al. Mechanism of action and impact of a cystitis clinical practice guideline on outcomes and costs of care in an HMO. Jt Comm J Qual Improv 1996; 22: 673-82
129. Taur Y, Smith MA. Adherence to the Infectious Diseases Society of America guidelines in the treatment of uncomplicated urinary tract infection. Clin Infect Dis 2007 Mar 15; 44 (6): 769-74
130. Kahan NR, Chinitz DP, Waitman DA, et al. Empiric treatment of uncomplicated UTI in women: wasting money when more is not better. J Clin Pharm Ther 2004 Oct; 29 (5): 437-41
131. Kahan NR, Chinitz DP, Kahan E. Longer than recommended empiric antibiotic treatment of urinary tract infection in women: an avoidable waste of money. J Clin Pharm Ther 2004 Feb; 29 (1): 59-63
132. Kahan NR, Chinitz DP, Kahan E. Physician adherence to recommendations for duration of empiric antibiotic treatment for uncomplicated urinary tract infection in women: a national drug utilization analysis. Pharmacoepidemiol Drug Saf 2004 Apr; 13 (4): 239-42
133. Le TP, Miller LG. Empirical therapy for uncomplicated urinary tract infections in an era of increasing antimicrobial resistance: a decision and cost analysis. Clin Infect Dis 2001 Sep 1; 33 (5): 615-21
134. Berger RE. Duration of antibacterial treatment for uncomplicated urinary tract infection in women. J Urology 2006 Mar; 175 (3): 968
135. Nickel JC. Management of urinary tract infections: historical perspective and current strategies: part 2, modern management. J Urology 2005 Jan; 173 (1): 27-32
136. Gentry LO. Cephalosporins in urinary tract infection. Drugs 1987; 34 Suppl. 2: 154-63
137. Miller LG, Mehrotra R, Tang AW. Does in vitro fluoroquinolone resistance predict clinical failure in urinary tract infections? Int J Antimicrob Agents 2007; 29: 605-7
138. Stamey TA, Fair WR, Timothy MM, et al. Serum versus urinary antimicrobial concentrations in the cure of urinary-tract infections N Engl J Med 1974 Nov 28; 291(22): 1159-1163
139. Kaiser J, McPherson V, Kaufmann L. Which UTI therapies are safe and effective during breastfeeding? J Fam Prac 2007 Mar; 56 (3): 225-6, 228
140. Johnson JR, Owens K, Gajewski A, et al. Escherichia coli colonization patterns among human household members and pets, with attention to acute urinary tract infection. J Infect Dis 2008 Jan 15; 197 (2): 218-24
141. Ong CL, Ulett GC, Mabbett AN, et al. Identification of type 3 fimbriae in uropathogenic Escherichia coli reveals a role in biofilm formation. J Bacteriol 2008 Feb; 190 (3): 1054-63